Results 71 to 80 of about 1,701 (184)
VirusesRetroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase.
Irene Wanjiru Kiarie +6 more
doaj +1 more source
Advanced Intelligent Discovery, Volume 2, Issue 5, October 2026.This study integrates random matrix theory (RMT) and principal component analysis (PCA) to improve the identification of correlated regions in HIV protein sequences for vaccine design. PCA validation enhances the reliability of RMT‐derived correlations, particularly in small‐sample, high‐dimensional datasets, enabling more accurate detection of ...
Mariyam Siddiqah +3 more
wiley +1 more source
Practical synthesis of 7-bromo-4-chloro-1H-indazol-3-amine: an important intermediate to Lenacapavir [PDF]
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections.
Naeem, Asad +9 more
core +2 more sources
The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.Abstract Cisgender women face an increased risk of HIV acquisition during pregnancy and postpartum. Oral pre‐exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (F/TDF) is recommended in pregnancy despite limited published pharmacokinetic (PK) and efficacy data during pregnancy.
Yifan Yu +17 more
wiley +1 more source
Bridging the Gap: The PrEP Cascade Paradigm Shift for Long-Acting Injectable HIV Prevention
VirusesLong-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) demonstrates superior efficacy and persistence compared to daily oral PrEP. However, real-world implementation reveals that only 52.9% of prescribed individuals initiate treatment with their ...
Adrian Charles (AC) Demidont
doaj +1 more source
Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.ABSTRACT Introduction The availability of highly efficacious HIV pre‐exposure prophylaxis (PrEP) makes it unethical or infeasible to conduct inactive/placebo‐controlled trials to evaluate new HIV prevention options. As a result, randomized active‐control non‐inferiority trials are typically employed; however, they require large sample sizes and ...
Fei Gao +16 more
wiley +1 more source
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study [PDF]
BACKGROUND: Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits. We evaluated treatment with two antibodies that broadly and potently neutralise HIV
VanderVeen, Laurie A +16 more
core +2 more sources
Journal of the International AIDS Society, Volume 29, Issue 9, September 2026.ABSTRACT Introduction Daily oral pre‐exposure prophylaxis (PrEP) use remains low among adolescent girls and young women (AGYW). We evaluated whether a peer support intervention improved daily oral PrEP uptake and adherence among AGYW at high risk of HIV acquisition in Kampala, Uganda.
Yunia Mayanja +8 more
wiley +1 more source
mBioHuman immunodeficiency virus type 1 (HIV-1) capsid, which is the target of the antiviral lenacapavir, protects the viral genome and binds multiple host proteins to influence intracellular trafficking, nuclear import, and integration.
Zachary Ingram +12 more
doaj +1 more source
Transfusion, Volume 66, Issue 11, Page 2397-2409, November 2026.
Nabiha H. Saifee +24 more
wiley +1 more source